The Food and Drug Administration (FDA) has given final approval for the generic version of cetirizine hydrochloride syrup (Zyrtec), according to Taro Pharmaceutical Industries.
Taro's cetirizine hydrochloride syrup is a bioequivalent to McNeil Consumer Healthcare's Zyrtec Syrup 1 mg/mL, and is used for symptom relief associated with perennial allergic rhinitis in children 6 to 23 months old and for chronic urticaria in children 6 months to 5 years old. Taro had received tentative FDA approval for Zyrtec in October 2007.
Further details on the approval may be found on the FDA website.
